Journal of psychosomatic research · 2026
Mindfulness-based stress reduction for functional neurological disorder: A feasibility study.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Michaelis Rosa, Meibert Jörg, Alimov Nicole, Kleinschnitz Christoph, Popkirov Stoyan
Аннотация
BACKGROUND: Functional neurological disorder (FND) is common and associated with substantial disability, yet evidence-based treatment options remain limited. Because maladaptive attentional processes are central to FND pathophysiology, mindfulness-based interventions may be beneficial. Mindfulness-Based Stress Reduction (MBSR) has strong empirical support across physical and mental health conditions, but evidence in FND is sparse.
OBJECTIVES: To assess feasibility, acceptability, and preliminary clinical outcomes of MBSR for patients with FND.
METHODS: In this monocentric, single-arm feasibility study, German-speaking adults with confirmed FND were recruited from a specialized outpatient clinic. Participants completed an 8-week standardized MBSR program across three course cycles (two in-person, one online). Primary outcomes included recruitment, retention, attendance, and self-reported home practice; acceptability was assessed via recommendation likelihood. Secondary outcomes included health-related quality of life (WHODAS 2.0), functional impairment (WSAS), depressive (PHQ-9) and anxiety symptoms (GAD-7), and FND symptom burden (FNSQ). Assessments occurred at baseline, post-intervention, and three-month follow-up.
RESULTS: Of 57 eligible patients, 24 enrolled (42%); 22 completed the course (92%). Recommendation likelihood was high. Statistically significant pre-post improvements were observed in WHODAS 2.0 (d = -0.56) and WSAS (d = -0.67), with comparable values at three-month follow-up. Post-intervention PHQ-9 scores improved (d = -0.75), FNSQ symptom count decreased (d = -0.68), whereas GAD-7 changes were nonsignificant. Online delivery demonstrated particularly strong adherence without dropouts.
CONCLUSIONS: MBSR for FND is feasible and well-accepted. A randomized controlled trial is warranted to determine efficacy. Future research could serve as a model for transforming patient-centered care in the digital era.
CLINICAL TRIAL REGISTRATION NUMBER: German Clinical Trials Register (DRKS00034806).
OBJECTIVES: To assess feasibility, acceptability, and preliminary clinical outcomes of MBSR for patients with FND.
METHODS: In this monocentric, single-arm feasibility study, German-speaking adults with confirmed FND were recruited from a specialized outpatient clinic. Participants completed an 8-week standardized MBSR program across three course cycles (two in-person, one online). Primary outcomes included recruitment, retention, attendance, and self-reported home practice; acceptability was assessed via recommendation likelihood. Secondary outcomes included health-related quality of life (WHODAS 2.0), functional impairment (WSAS), depressive (PHQ-9) and anxiety symptoms (GAD-7), and FND symptom burden (FNSQ). Assessments occurred at baseline, post-intervention, and three-month follow-up.
RESULTS: Of 57 eligible patients, 24 enrolled (42%); 22 completed the course (92%). Recommendation likelihood was high. Statistically significant pre-post improvements were observed in WHODAS 2.0 (d = -0.56) and WSAS (d = -0.67), with comparable values at three-month follow-up. Post-intervention PHQ-9 scores improved (d = -0.75), FNSQ symptom count decreased (d = -0.68), whereas GAD-7 changes were nonsignificant. Online delivery demonstrated particularly strong adherence without dropouts.
CONCLUSIONS: MBSR for FND is feasible and well-accepted. A randomized controlled trial is warranted to determine efficacy. Future research could serve as a model for transforming patient-centered care in the digital era.
CLINICAL TRIAL REGISTRATION NUMBER: German Clinical Trials Register (DRKS00034806).